#Immunotherapy is an active hashtag on Bluesky. In the last 30 days, 66 people shared 107 posts with it — around 4 a day. Activity is down 36% versus the previous week, peaking on Sep 10 with 11 posts.
Tags most often used together with #Immunotherapy.
www.science.org
TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function
Modulation of exhausted CD8+ T cell differentiation by targeting TET2 improves therapeutic potential of CAR T cells in cancer.
www.nature.com
Keeping the immuno-oncology flame burning
Ira Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy, asks why so many drug developers are retreating from immune-modulating drugs, cell therapies and cancer vac...
www.the-scientist.com
Why Are Breast Cancers That Metastasize to the Brain Hard to Treat?
Immunosuppressive factors prevent killer T cells from defeating brain tumors that arise from primary breast cancer.
www.embopress.org
Interferon-induced PARP14-mediated ADP-ribosylation in p62 bodies requires the ubiquitin-proteasome system | The EMBO Journal
imageimageInterferon induces the formation of ADP-ribosylation (ADPr)-enriched p62 bodies, requiring PARP14 and p62. Unlike canonical p62 bodies, these ADPr-enriched structures are independent of auto...
www.cell.com
Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation
The serine/glycine-free diet inhibits CRC growth and enhances antitumor immunity but also promotes immune evasion through PD-L1 lactylation. It shows promise when combined with immunotherapy and has been proven feasible and safe in a single-arm, phase I trial.
The Innovation | Medicine @innovationmedicine.bsky.social
The serine/glycine-free diet, like Athena’s dual approach in warfare, boosts tumor visibility (MHC-I) while inducing PD-L1 lactylation as a shield. PD-1 inhibitors, akin to Athena’s wisdom, neutralize this defense, enabling immune attack. Clinical trials confirm its promising synergy.
scim.ag
Interleukins 15 and 18 synergistically prime the antitumor function of natural killer cells through noncanonical activation of mTORC1
mTORC1 activation by components of a cytokine cocktail enhances NK cell cytotoxicity toward cancer cells.
www.cell.com
The local microenvironment suppresses the synergy between irradiation and anti-PD1 therapy in breast-to-brain metastasis
Wischnewski et al. demonstrate suppressed CD8+ T cell cytotoxicity in breast cancer brain metastases, contrasting with genetically identical extracranial tumors. Neutrophils and Trem2+ macrophages dri...
dlvr.it
ASCO GI 2025 SoMe Report.pdf
Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.
third-news.com
Cancer Vaccines Market Anticipated to Witness Rapid Growth of 36% CAGR from 2026 to 2036
The cancer vaccines market is set for remarkable growth, driven by increased cancer incidence and innovative therapies. This report explores key developments and forecasts.
pmc.ncbi.nlm.nih.gov
A Multimodal Framework to Guide Solid Tumor Indications for Natural Killer Cell‐Based Therapy
T cell‐based immunotherapies have achieved remarkable success in hematological malignancies but remain limited in solid tumors. Natural killer (NK) cells offer a compelling complementary approach, giv...
www.dana-farber.org
Making invisible cancers visible: Study suggests a new route to turn ‘cold’ tumors ‘hot’ | Dana-Farber Cancer Institute
One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see. New research from Dana-Farber Cancer Institute scient...
dlvr.it
A multimodal murmuration for immunotherapy - Nature Medicine
A study shows that integrating numerous multimodal, patient-level biomarkers enhances the prediction of cancer immunotherapy response, but generalizability is still a challenge.
en.killbait.com
Novel Nanoparticle System Targets Tumor Microenvironment to Enhance Immune Response in Cancer Therapy
The article discusses a groundbreaking cancer therapy developed by researchers at the University of Adelaide, led by Professor Chunxia Zhao. The treatment utilizes 'smart' nanoparticles to deliver mRNA directly to tumor sites, specifically targeting tumor-associated macrophages that have been reprogrammed by cancer to suppress immune responses. The mRNA carries instructions for producing CXCL9, a chemical signal that recruits T cells, which are critical for attacking cancer cells. The nanoparticles are designed with antibodies that bind to TREM2, a protein found on immunosuppressive macrophages, ensuring precise delivery to the tumor microenvironment. Additionally, the nanoparticles carry resiquimod, a drug that stimulates immune pathways. Laboratory results showed that macrophages began producing CXCL9 and other immune markers, with NOS2 expression increasing by 89.5 times. In mouse models with aggressive breast cancer, three doses of the therapy slowed tumor growth, increased CXCL9 concentration by four times compared to controls, and enhanced T-cell activity. The treatment also reduced immunosuppressive macrophages by 63 percent. When combined with existing immunotherapies like checkpoint inhibitors, the therapy showed increased T-cell diversity within tumors and lymph nodes, suggesting potential for more durable immune responses. The researchers emphasized that while the results are promising, further studies are needed to assess safety before human trials. Professor Zhao described this as an important proof of concept for reprogramming the tumor immune environment using mRNA and nanoparticle technology, laying the groundwork for more targeted cancer immunotherapies. The article highlights the potential of mRNA technology, previously popularized by COVID-19 vaccines, to be adapted for cancer treatment with enhanced precision and reduced side effects through targeted delivery systems.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.
